Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Diacerein - Neopharmed Gentili

Drug Profile

Diacerein - Neopharmed Gentili

Alternative Names: Art 50; Artrodar; Artrolyt; Cartivix; Diacerhein; Diacetylrhein; Fisiodar; Galaxdar; KW 4800; Matrix; Rhein diacetate; SF 277; Verboril

Latest Information Update: 06 Sep 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Istituto Gentili; Proter
  • Developer Abiogen Pharma; Ecupharma; Faran; Kyowa Kirin; Lacer; Myungmoon Pharm; Neo-Farmaceutica; Neopharmed Gentili; Proter; TRB Pharma; Wockhardt
  • Class Anthraquinones; Anti-inflammatories; Antihyperglycaemics; Antirheumatics; Skin disorder therapies; Small molecules
  • Mechanism of Action Caspase 1 inhibitors; Interleukin 1 beta inhibitors; NLRP3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Osteoarthritis

Most Recent Events

  • 06 Sep 2022 No development reported - Phase-III for Osteoarthritis in Canada (PO) (NDR Batch 23)
  • 27 Jul 2022 Lacer has been acquired by Italfarmaco
  • 22 Nov 2020 TRB Chemedica initiates enrolment in a phase III trial for Osteoarthritis (In adults, In elderly) in Thailand(PO, Capsule) (NCT04318041)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top